{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"ORR is presented in this outcome measure as number of responders.","groups":[{"description":"Participants with CTCL who received study drug in part 4.","id":"OG000","title":"Part 4: CTCL"}],"populationDescription":"Data for this outcome measure is not available as analysis was not performed because: 1) due to futility and heterogenicity of respective data of the parameters of organ system (i.e., skin, blood, lymph node, and viscera; 2) the Olsen 2011 criteria already defined the \"Global Response Score\" to determine the Global Response (GR) consisting of the 4 components which (GR) was more important assessment affecting overall prognosis.","reportingStatus":"POSTED","timeFrame":"From first dose of study till the progressive disease/death or withdrawal (maximum observation 6 years 10 months)","title":"Part 4: Overall Response Rate (ORR) in Cutaneous T-Cell Lymphoma (CTCL) Both Fungoides and Sezary Syndrome","type":"SECONDARY"}